Segment Information

3 Months Ended

Mar. 31, 2022

Segment Reporting [Abstract]

Segment Information

Segment Information

We periodically evaluate our application of accounting guidance for reportable segments and disclose information about reportable segments based on the way management organizes the enterprise for making operating decisions and assessing performance. We report our business under two segments: Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment includes our United States distribution business (Medical Distribution), outsourced logistics and value-added services business, and Global Products which manufactures and sources medical surgical products through our production and kitting operations. The Patient Direct segment includes our home healthcare businesses (Byram and Apria).

We evaluate the performance of our segments based on their operating income excluding intangible amortization and acquisition-related and exit and realignment charges that, either as a result of their nature or size, would not be expected to occur as part of our normal business operations on a regular basis. Segment assets exclude inter-segment account balances as we believe their inclusion would be misleading and not meaningful.

The following tables present financial information by segment:

	Three Months Ended  March 31,
	2022		2021
Net revenue:
Products & Healthcare Services	$	2,134,041	$	2,109,445
Patient Direct	272,911		217,089
Consolidated net revenue	$	2,406,952	$	2,326,534
Operating income:
Products & Healthcare Services	$	89,083	$	150,418
Patient Direct	15,793		12,263
Intangible amortization	(10,269)		(10,026)
Acquisition-related and exit and realignment charges	(33,548)		(5,963)
Consolidated operating income	$	61,059	$	146,692
Depreciation and amortization:
Products & Healthcare Services	$	18,994	$	19,160
Patient Direct	5,131		3,740
Consolidated depreciation and amortization	$	24,125	$	22,900
Capital expenditures:
Products & Healthcare Services	$	10,643	$	6,464
Patient Direct	318		159
Consolidated capital expenditures	$	10,961	$	6,623

	March 31, 2022		December 31, 2021
Total assets:
Products & Healthcare Services	$	2,960,748	$	3,012,303
Patient Direct	2,535,923		468,536
Segment assets	5,496,671		3,480,839
Cash and cash equivalents	211,298		55,712
Consolidated total assets	$	5,707,969	$	3,536,551

The following table presents net revenue by geographic area, which were attributed based on the location from which we ship products or provide services.

	Three Months Ended March 31,
	2022		2021
Net revenue:
United States	$	2,262,019	$	2,182,755
International	144,933		143,779
Consolidated net revenue	$	2,406,952	$	2,326,534